Platelet-Rich Plasma Therapy for Knee Joint Problems: Review of the Literature, Current Practice and Legal Perspectives in Korea by Park, Yong-Geun et al.
to heal the injured tissue
1,2). Its use is reported in the fields of 
dermatology, plastic surgery, dentistry, otolaryngology, urology, 
ophthalmology, and neurosurgery. In the fields of orthopedics 
and sports medicine, some clinicians have applied PRP therapy in 
acute ligament injury (medial collateral ligament rupture of knee 
joint, lateral collateral ligament rupture of ankle, etc.), chronic 
tendon problems (rotator cuff tear, lateral epicondylitis of elbow, 
tendinitis around the knee joint, Achilles tendinitis, plantar 
fasciitis, etc.), acute muscle rupture, or facilitation of bone healing 
after bone graft. Experimentally, it has also been applied in 
intraarticular injections for chondromalacia or osteoarthritis
1-5). 
However, most clinical reports on PRP in orthopedics and 
sports medicine are case reports or case-series studies without 
a control group (evidence level IV), or do not have enough 
statistical significance due to their small sample size
2). Since most 
growth factors are secreted within one hour after intraarticular 
PRP injection, PRP cannot alter the pathophysiology of chronic 
diseases such as osteoarthritis, and it is difficult to expect that 
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Platelet-rich plasma (PRP) is a concentrate extract of platelets from autologous blood, and represents a possible treatment option for the stimulation 
and acceleration of soft-tissue healing and regeneration in orthopedics. Currently, the availability of devices for outpatient preparation and delivery 
contributes to the increase in the clinical use of PRP therapy in practical setting of orthopedic fields. However, there is still paucity of scientific 
evidence in the literature to prove efficacy of PRP therapy for the treatment of ligament or tendon problems around the knee joint. Moreover, strong 
evidence from well-designed clinical trials to support the PRP therapy for osteoarthritis of the knee joint is yet scanty in the literature. Scientific 
studies need to be performed to assess clinical indications, efficacy, and safety of PRP, and this will require high powered randomized controlled 
trials. Nonetheless, some hospitals exaggeratedly advertise PRP procedures as the ultimate treatment and a novel technology with abundant scientific 
evidence for the treatment of knee problems. As a matter of fact, PRP protocols are currently approved only for use in clinical trials and research, 
and are not allowed for treatment purpose by any institutions in Korea. At present, clinical use of PRP therapy for ligament or tendon problems or 
osteoarthritis of knee joint is defined as illegal medical practice, regardless of whether it is performed as a sole procedure or as a part of prolotherapy, 
because the safety and validity are not yet approved by the Ministry of Health and Welfare and Health Insurance Review and Assessment Service. 
Practicing physicians should remember that injection of PRP to patients by imposing medical charge is still illegal as per the current medical law in 
Korea.
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Introduction
Platelet-rich plasma (PRP) is a concentrate extract of platelets 
from autologous blood. It is known to increase growth factor 
concentration three to five times of normal plasma and helps 
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cartilage that is already worn out will regenerate with that short 
exposure to growth factors.
Related institutions such as the Ministry of Health and the 
National Evidence-based Healthcare Collaborating Agency have 
stated their position that it is illegal to perform PRP procedures 
and charge patients for the procedures whose safety and efficacy 
have not yet been proven. Nevertheless, PRP procedures are 
receiving the spotlight as a new profit-making model, and several 
hospitals are advertising about such procedures through the 
internet and other media.
It is a big concern in terms of socio-economic costs and national 
health levels that PRP procedures are spreading indiscreetly 
without sufficient medical evidence. Moreover, even the safety of 
the procedures has not yet been fully established. Furthermore, 
PRP procedures are being abused by some hospitals as a means 
of unjust profit-making and hospital advertisement, which 
can transfer relative disadvantages to the majority of medical 
institutions that follow honest evidence-based medicine. It is 
important to note that although some novel medical technologies 
develop and improve through critics and mistakes, many are 
discarded due to problems in safety and validity
6,7).
Therefore, we enclosed the current situation of PRP-related 
exaggerative advertisements in Korea, review of the current 
literatures to discover what scientific evidence we currently do 
have regarding the PRP therapy around the knee joint, and the 
perspectives of the Korean regulating organizations in terms 
of the legal issues in this review. Accordingly, we would like to 
provide a reference for the practicing physicians with regard to 
the clinical applications and researches with PRP.
The Current Situation of PRP-related Exaggerative 
Advertisements in Korea
Advertisements of PRP procedures can be found in news-
papers, TV broadcasts, and hospital promotion sites. They are 
mostly found on digital free newspapers, internet versions of 
major newspapers, and hospital promotion sites. In addition, 
information in certain advertisements are being quoted in blogs, 
knowledge sites, and Q&A sites, making it difficult for non-
medical public to judge such contents objectively. The titles and 
contents of these advertisements describe PRP as the primary 
or ultimate treatment for the certain disease mentioned in the 
advertisement, and PRP is described as a cutting-edge medical 
technology with scientific evidence.
The problems regarding those advertisement contents can be 
summarized as the followings: First, the number of PRP-related 
articles is increasing. Starting from the article introducing PRP 
prolotherapy in March, 2009 (OSEN entertainments 2009-3-21), 
the number is increasing annually: 10 articles in 2009, 168 articles 
in 2010, and 248 articles in 2011.
Second, the advertised indications for PRP procedures are 
broadening, and the therapeutic benefits being described are 
becoming more and more exaggerated. One article in April 2009 
stated that PRP prolotherapy may be an alternative treatment 
in acute injury of the hamstring (tendon) (OSEN living/culture 
2009-4-23). However, in 2011, there were articles that stated 
PRP as the (a) fundamental therapy for cartilage strengthening 
(Segye Press 2011-04-11), that meniscus tear is treatable by PRP 
without surgery (Sports world 2011-08-28), that 3 injections 
of PRP in cartilage injury can eliminate pain (Health Chosun 
2011-10-04), and that avascular necrosis of the femoral head can 
also be completely healed with PRP (Sports world 2011-12-14). 
These examples are only to mention a few, and other numerous 
indications and exaggerated therapeutic benefits are being 
reported with hospital advertisements.
Third, PRP-related advertisements are concentrated on only a 
few hospitals. Over 90% of PRP-related articles in the orthopedic 
and sports medicine area are from ‘Y’ hospital, ‘T’ hospital, ‘L’ 
clinic, ‘S’ clinic, etc. It is worrisome that the majority of medical 
institutions, which do not perform PRP procedures due to the 
lack of validity and legal restrictions, may be perceived by the 
public as “not up to date”.
Fourth, the so-called evidence most PRP-related articles bring 
up as the basis of their contents was game results of overseas 
sports stars who have received PRP procedures (such as Tiger 
Woods, Hines Ward, Kobe Bryant) or case reports published on 
small foreign journals reported by doctors who performed such 
PRP procedures
8). It is difficult for the general public to discern 
whether the effects of PRP procedures described in these articles 
are really based on scientific objectivity.
Fifth, articles about results of PRP-related research done by 
a few academic institutions are quoted in other articles. The 
research results of PRP application to knee cartilage diseases 
by the Catholic University Uijeongbu St. Mary’s Hospital 
(Medicaltoday 2011-08-12) were quoted 4 times in other articles, 
and the research results of PRP application to rotator cuff tear by 
Kwandong University Myongji Hospital (Segyeilbo 2011-05-16) 
were quoted 3 times in other articles. We must remind ourselves 
that reports of PRP-related research results from academic 
institutions described in these articles could be accepted by the 
public, who do not have an idea on clinical research and have 
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the safety and validity of PRP procedures for most orthopedic 
problems.
What is fortunate is that there are some articles that point 
out the validity and legal aspects of PRP procedures. Examples 
include the article quoting New York Times and explains that 
PRP procedures are not effective (Chosunilbo 2011-09-09), 
articles that reported the abusive use of PRP procedures (Money 
Today 2011-09-29, Medipharm News 2011-10-19, Korean 
Healthlog 2011-10-23), articles saying that PRP procedures have 
no medical evidence (Doctor’s News, Money Today, Korea Health 
Log 2011-11-03), and the article saying that PRP procedures are 
illegal under current medical law (Korea Health Log 2011-09-
30, 2011-10-19). These articles could be used by hospitals that 
do not perform PRP procedures when patients demand such 
procedures.
Advertising uncertain material about PRP procedures through 
the press and wrongly applying such procedures to general 
patients is certainly a harmful deed both in the socioeconomic 
point of view and the national public health point of view. Such 
deeds also make the public see honest hospitals that do not 
perform such procedures as if they are incompetent hospitals 
that do not care about novel medical technologies. PRP is yet a 
new procedure only in the early research stage. Its effectiveness 
is not medically proven, and especially so in chronic diseases 
such as degenerative osteoarthritis. Arguments about the efficacy 
of PRP in degenerative osteoarthritis should be made carefully 
and only in the academic research field. Carelessly advertising 
such material to the public can be an act of false or exaggerated 
advertisement without medical evidence.
Therefore, efforts must be made by medical facilities, the press, 
and related government institutions to clear away such false 
or exaggerated material. Also, it would be reasonable that only 
papers describing clinical results collected with patient consent 
under strict control of institutional review boards and published 
by academic journals make it into general newspaper articles.
PRP: Literature Review of Clinical Use around Knee 
Joint
PRP represents a possible treatment option for the stimulation 
and acceleration of soft-tissue healing and regeneration. Use 
of PRP treatment has expanded in the field of sports medicine 
because it is autogenously originated and easily prepared. 
According to the recently reported literature reviews, the level 
of current research lacks enough scientific evidence to prove 
safety and effectiveness of PRP treatment, and it emphasized that 
more research needs to be carried out with randomized, double-
blind methods
2,9-13). Despite the lack of scientific evidence on 
the effectiveness of PRP, the availability of devices for outpatient 
preparation and delivery of PRP has contributed to the increase 
in the clinical use of PRP treatment.
1. PRP for Ligaments or Tendons around Knee Joint
The healing process of ligament and tendon is extremely 
complex and not fully understood with regard to the actions 
among stimulatory, inhibitory, and regulatory factors
14). In this 
setting, it has not been fully recognized how and when injection 
of growth factor or PRP into damaged tissue stimulates the 
healing process. Kajikawa et al.
14) reported that PRP increased 
the number of collagen fiber and fibroblast in the early phase of 
healing process after the damage to tendon of rats. PRP is known 
to stimulate the synthesis of hepatocyte growth factor (HGF) and 
vascular endothelial growth factor (VEGF) present in the tendon 
cells, which in turn increases cellular proliferation and vascular 
regeneration. However, the balance between transforming growth 
factor-β1 (TGF-β1) and the pools of platelet-secreted molecules 
may have important therapeutic implications in the control of 
angiogenesis and fibrosis
15). Murray et al.
16) reported that addition 
of PRP to the suture repairs of anterior cruciate ligament (ACL) 
did not improve anterior-posterior knee laxity, maximum tensile 
load, or linear stiffness of the ACL repairs after 14 weeks in vivo. 
They concluded that use of PRP alone to supplement suture 
repair of the ACL was ineffective in the animal model and they 
were confident that a clinically meaningful effect as a result of 
adding PRP was unlikely.
Although there have not been enough clinical research on 
the effects of growth factor and PRP on chronic tendon injury, 
it has been considered to be used for chronic tendinopathy 
due to the need for effective conservative therapies and basic 
research result of its effectiveness on angiogenesis and collagen 
synthesis
3,17). Filardo et al.
18) compared PRP injection group 
(n=15) to the control group (n=16), for patients with chronic 
jumper’s knee who had failed previous nonsurgical or surgical 
treatments regarding, Tegner scale, EQ-Visual Analogue Scale 
(EQ-VAS) scale, and pain level. Even though the group with 
PRP injection showed higher scores on all the criteria, its 
outcome indicated no statistical significance when compared 
to the control group. Coombes et al.
19) performed a systematic 
review of randomized trials to establish clinical efficacy and risk 
of adverse events for treatment by injection. The result of the 
analysis of 2672 participants showed that PRP were not more 
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prolotherapy was not more effective than was eccentric exercise. 
Hart
20) also performed a database search using terms describing 
common tendinopathies and injections, including steroids, local 
anesthetics, sclerosing solutions, aprotinin, PRP, botulinum 
toxins, and glycosaminoglycans to determine the efficacy and 
risk of adverse effects of peritendinous corticosteroid and other 
injections in the management of tendinopathy. Based on the 
review of 174 papers, they concluded that corticosteroid injection 
is beneficial in the short term for the treatment of tendinopathies 
but may be worse than other treatments in the intermediate and 
long terms, and no clear evidence of benefit of other injections 
was shown, except for sodium hyaluronate in the short and 
long term in overall improvement and pain reduction of lateral 
epicondylalgia (1 study). Therefore, the effect of PRP injections 
for chronic tendinopathy is currently not proven. de Vos et al.
21) 
revealed in their report of systemic review of autologous growth 
factor injection (whole blood or PRP) for chronic tendinopathy 
that although all studies showed that injections of autologous 
growth factors (whole blood and PRP) in patients with chronic 
tendinopathy had a significant impact on improving pain and/
or function over time, only three studies using autologous whole 
blood had a high methodological quality assessment, and none 
of them showed any benefit of an autologous growth factor 
injection when compared with a control group. They emphasized 
that there was strong evidence that the use of injections with 
autologous whole blood should not be recommended. They also 
emphasized that there were no high quality studies found on 
PRP treatment, and thus, there was limited evidence to support 
the use of injections with PRP in the management of chronic 
tendinopathy. Currently, there is lack of scientific evidence that 
PRP injection is more effective or results in earlier return-to-
sport rates than other inert injections.
Although there are some reports about the use of PRP injection 
in the ACL reconstruction, they failed to provide any statistical 
difference in treatment outcomes between the treatment 
group and the control group. Sanchez et al.
22) have performed 
postoperative assessment in patients who had plasma rich in 
growth factors (PRGF) assisted (n=15) and the conventional ACL 
reconstruction (n=22) on arthroscopic and pathologic evaluation 
at 6 to 24 months. The use of PRGF influenced the histologic 
characteristics of tendon grafts, resulting in more remodeling 
compared with untreated grafts. However, arthroscopic 
evaluations were not statistically different between PRGF and 
control groups. Cervellin et al.
23) performed randomized control 
study about the application of autologous PRP gel to the donor 
site after ACL reconstruction with patellar tendon graft. At the 
12-month follow-up, the postoperative evaluation using VAS and 
Victorian Institute Sport Assessment (VISA) scale and magnetic 
resonance imaging (MRI) evaluation was implemented on 
both autologous PRP treatment group (n=20) and the control 
group (n=20). Although evaluation using VISA scale revealed 
that effectiveness of autologous PRP treatment was statistically 
significant, the VAS scale showed no statistical difference 
between the 2 groups. The recovery of the tibial and patellar bone 
defects by new bony tissues in both groups was equally successful 
and showed no statistical differences. The results of the study 
indicated no effectiveness of autologous PRP in subjective pain 
reduction at the donor site after the ACL reconstruction. Vogrin 
et al.
24) performed prospective randomized double-blind study 
on the effect of platelet gel on early graft revascularization after 
ACL reconstruction. After grouping those treated with platelet 
gel (n=25) and those in the control group (n=25), contrast-
enhance MRI was used to assess revascularization process in 
the osteoligamentous interface zone in the bone tunnel and in 
the intra-articular part of the graft. The treatment group showed 
faster revascularization in the osteoligamentous interface zone in 
the tibial bone tunnel, however, there was no statistical difference 
in the intra-articular part of the graft between the two groups. 
Nin et al.
25) performed prospective randomized study on 100 
patients who had ACL reconstruction with allograft after dividing 
them into the PRP treatment group (n=50) and the control 
group (n=50), and its evaluation was based on 2-year follow-up, 
radiologic, and MRI assessment. The 2-year follow-up assessment 
revealed that the use of platelet derived growth factor (PDGF) 
had no noticeable clinical or biomechanical effect. Orrego et al.
26) 
studied the effects of platelet concentrate and a bone plug on the 
healing of hamstring tendons in a bone tunnel. After randomly 
dividing 108 patients requiring ACL reconstruction into control 
(n=26), platelet concentrate (n=26), bone plug (n=28), and 
a combination of platelet concentrate and bone plug (n=27) 
groups, MRI studies were prospectively carried out to compare 
the healing of hamstring tendons in a bone tunnel. The use of 
platelet concentrate only had enhancing effects on the maturation 
process of the graft but lacked effects on improvement in the 
osteoligamentous interface or tunnel widening evolution. Silva 
and Sampaio
27) also reported that treatment and control group 
showed no differences in signal intensity at the tendon bone 
interface on MRI at the 3-month follow-up. Despite some case 
or case series reports about the effect of PRP on accelerating the 
early recovery from tendon injury, PRP injection is currently not 
recommended in ACL reconstruction surgery, which is proven to 
have no efficacy in the human randomized controlled trials.74    Park et al. Platelet-Rich Plasma Therapy for Knee Joint Problems
2. PRP for Articular Cartilage Defect or Osteoarthritis of Knee 
Joint
Articular cartilage injuries and degenerative joint disease are 
one of the most challenging and actively researched field in 
orthopedic surgery and sports medicine. Woodell-May et al.
28) 
reported that the autologous protein solution (APS) prepared 
from PRP contained both anabolic (bFGF, TGF-β1, TGF-β2, 
EGF, IGF-1, PDGF-AB, PDGF-BB, and VEGF) and anti-
inflammatory (IL-1ra, sTNF-R1, sTNF-RII, IL-4, IL-10, IL-
13, and IFNγ) cytokines, and that the combination of these 
cytokines is a potential candidate for treatment of osteoarthritis. 
van Buul et al.
29) suggested that PRP influences conversion of 
human osteoarthritic chondrocytes by inhibiting the action 
of inflammatory cytokines such as IL-1 and NF-kB. However, 
despite the possibilities based upon the result of some in vitro 
studies, there is still a lack of evidence to support the effect of 
PRP in the treatment of osteoarthritis in humans.
In some studies, the combination of microfracture procedure 
and PRP injection in cases of osteochondral injuries showed that 
PRP injection was helpful in enhancing the effect of microfracture 
treatment, but the treatment effectiveness of PRP injection alone 
has not been studied yet. Milano et al.
30) performed experimental 
studies on the effect of autologous PRP with microfracture on 
chondral defects in a sheep model, and reported that treatment 
with PRP revealed advantageous effect on improvement of 
cartilage stiffness and showed higher International Cartilage 
Repair Society (ICRS) scores. Dhollander et al.
31) has introduced a 
surgical technique about PRP gel application after microfracture 
procedure on 5 patients suffering from osteochondral patellar 
lesions in the knee and reported clinical improvement among the 
patients at the 24-month follow-up.
Intra-articular injection of autologous PRP has been increas-
ingly implemented on patients with osteoarthritis and currently 
seems to be considered as one of the treatment options for 
osteoarthritis. Most of the studies on autologous PRP injection 
have been focused on the reduction of pain and improvement 
of function over time. Sampson et al.
32) reported the results of a 
pilot study about the PRP injection on 13 patients with primary 
or secondary knee arthritis, showing improvement in pain and 
symptoms without adverse effect on the scales of Knee Injury 
and Osteoarthritis Outcome Scores (KOOS). Wang-Saegusa 
et al.
33) reported improvement of VAS, SF-36, and Western 
Ontario and McMaster Universities (WOMAC) scores at the 
6-month follow-up in 261 patients with OA symptoms more 
than 3 months who had 3 intra-articular injection of autologous 
PRGF at 2-week intervals. Filardo et al.
34) reported that 3 
injections of intra-articular PRP in 90 patients with chronic knee 
degenerative conditions revealed improvement in Internatioal 
Knee Documentaion Comitee (IKDC) and EQ-VAS scores 
at the 2-year follow-up and that it had discernible positive 
effects especially on younger patients with early osteoarthritis. 
Napolitano et al.
35) also reported improved outcome by reviewing 
27 patients with numerical rating scale (NRS) and WOMAC 
scores for 6 months. This study failed to show differences in 
degree of outcome compared with other studies because it simply 
evaluated the clinical results before and after the treatment 
without control. Sanchez et al.
5) performed a retrospective cohort 
study on two groups who were treated with intra-articular 
injection of PRGF and with hyaluronic acid respectively and 
reported that PRGF treatment group showed improvement 
in pain and quality of life. Such effect was explained by action 
of PRGF in recovering the balance between intra-articular 
hyaluronic acid concentration and revascularization
36). It 
suggested short-term results through a retrospective (evidence 
level IV) study with a small sample size. Kon et al.
4) reported 
that intra-articular PRP injection in 100 patients with chronic 
degenerative condition of the knee had positive effects on 
improving pain and quality life and on the scores of IKDC and 
EQ-VAS at the 1-year follow-up. Kon et al.
37) divided 150 patients 
with knee cartilage degenerative lesions or osteoarthritis into 3 
groups, those treated with injections of autologous PRP (n=50), 
low hyaluronic acid concentration (n=50), and high hyaluronic 
acid concentration (n=50) and compared scores of IKDC and 
EQ-VAS among the groups at the 2-month and 6-month follow-
up respectively. It was reported that the group with injection of 
autologous PRP had better outcomes in aspects of pain reduction 
and recovery of articular function. Because the study did not 
utilize randomized double-blind method, only suggested short-
term clinical reports and did not consider statistical bias, this 
study was inadequate to conduct statistical analysis due to lack of 
prominent differences in clinical results. Spakova et al.
38) reported 
a comparison study of PRP vs. hyaluronic acid in Kellgren-
Lawrence grade 1, 2, or 3 osteoarthritis patients with better result 
in PRP group. The authors concluded that their preliminary 
findings supported the application of autologous PRP as an 
effective and safe method in the treatment of the initial stages of 
knee osteoarthritis and further studies were necessary to confirm 
these results and to investigate the persistence of the beneficial 
effects observed.
Previous studies on intra-articular PRP injection reported its 
advantageous effects in pain reduction and function recovery, but 
their methodology is still questionable. There are no comparative Knee Surg Relat Res, Vol. 24, No. 2, Jun. 2012    75
results in the effectiveness of PRP injection to placebo or control 
injection in a double-blind method, nor with prolonged follow-
up period. To date, there is still limited evidence about not 
only the effectiveness of PRP injection compared with other 
treatments on osteoarthritis but also strong recommendation 
toward PRP injection in treating osteoarthritis. Because of the 
cost-effectiveness, other treatments such as hyaluronic acid 
injection rather than PRP should be considered first. Studies need 
to implicate randomized double-blind using a proper control 
group to measure applicable treatment efficacy.
3. Recommendation for Using PRP
Since there is a lack of research evidence on treatment efficacy of 
PRP, preparation procedure, location and timing of injection, and 
amount of dosage to yield its clinical effectiveness has not been 
determined. The American Academy of Orthopedic Surgeons 
(AAOS)
39) and WellCare Health Plans
40), Inc have announced 
the PRP protocols only for use in clinical trials and research, and 
that PRP is not recommended for treatment purposes by any 
conferences or institutions in the world.
The Viewpoint of the Ministry of Health and Welfare 
and Health Insurance Review and Assessment 
Service on Using PRP and the Legal Issue
It is required to know the review procedure of a new medical 
technology in Korea so as to discuss the legality of PRP. Currently, 
according to the systematic device rules (article 3 Section 6 of 
rules on New Health Technology Assessment), the validity and 
safety of a new medical technology (treatment and operation, 
medicine, medical materials, etc.) should be assessed prior to 
use by the Committee for New Health Technology Assessment 
(hereinafter referred to as nHTA) in the country. In contrast, 
in the past, while an assessment of a new medical technology 
was conducted, it could be used until the result of assessment 
was released. However, such use is prohibited by the medical 
law at present. Thus, it is required to grasp the assessment 
report of nHTA and the position of Health Insurance Review 
and Assessment Service (hereinafter referred to as HIRAS) so 
as to identify the legality of the currently operated PRP or a 
prolotherapy that uses it.
1. Summary of the Report on the Assessment of Safety and 
Validity of PRP by nHTA
1) Applied technology: PRP
PRP is an operation to promote the healing or regeneration 
of tissue by applying the concentrated blood plasma in which 
the platelet extracted from own blood to the part where bone is 
damaged or soft tissue should be regenerated. As per article 53 
of medical law and article 3 of rules on New Health Technology 
Assessment, Autologous Platelet Rich Plasma Application, i.e., 
the new name of the terminology was applied on September 2, 
2009. 
2) Operation of nHTA and subcommittee 
In the 10th nHTA on October 23, 2009, PRP was judged as a 
new health technology that should be assessed in consideration 
of the fact that the materials from own blood are actively studied 
in diverse clinical areas these days. The nHTA decided to assess 
PRP in a subcommittee by systematically studying the literature. 
Composed of 5 members, the subcommittee was held 4 times 
for 5 months from Dec 3, 2009 to Apr 5, 2010 to assess the same 
operation on the basis of the literature and submitted the result of 
study. The result of assessing safety and validity of PRP was finally 
deliberated in the 4th nHTA (2010.4.23) on the basis of the same 
contents.
3) Assessment of PRP
(1) Objective of assessment: The objective is to assess whether 
PRP is a safe operation and effective for healing or regenerating 
tissue.
(2) Assessment method: The literature search strategy to assess 
PRP selected the degree of healing or regenerating tissue or the 
term spent for this work as main medical results of PRP injection 
in patients with damaged bone or patients whose soft tissue 
should be regenerated. For the assessment of PRP, 8 domestic 
databases including KoreaMed and foreign databases like Ovid-
MEDLINE, EMBASE and Cochrane Library were used. By 
searching strategy that uses the search word, ‘platelet rich plasma’, 
some 1,400 literatures were searched. Among the Korean and 
English literature in the proper type of study published after 2005 
(systematic investigation of literature, random clinic test study), 
the animal test or preclinic test study and study which is not an 
original book and gray literature were excluded. Further, study 
on patients in the area of dental clinic (oral and maxillofacial 
surgery) and the study included in the systematic investigation of 
literature included in assessment were also excluded. The 1,391 
units including redundantly searched literatures (396 units) were 
excluded and 9 studies (the systematic investigation of literature 
in 2 units, random clinic test study in 7 units) were finally 
included in the assessment.
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tion related to operation were assessed. The 2 systematic investi-
gation of literatures reported that there was no problem in the 
safety of PRP. Although a clear causal relation between PRP 
and death was not identified, 1 case of death due to cardiac 
causes among those to whom PRP was administered was 
reported in a random clinic test study on cardiovascular disease 
patients. The incidence of complication in the group using 
PRP was higher than that in the re-combination human bone 
morphogenetic protein 7 administered group in a comparative 
study and the same in the cellulose/collagen operating group 
in another comparative study. Further, it was reported that the 
group using PRP showed a similar rate of complications with 
the group without the use of PRP. Although complications 
included hematoma, re-operation, edema, seroma, infection, 
etc., it was difficult to find the exact relation with PRP. Thus, 
the subcommittee concluded 1) it was difficult to find an exact 
relation between the occurrence of complication and PRP, 
because the study targets in the selected literatures were diverse 
and specific presentation was deficient, 2) it was difficult to make 
positive conclusion on the safety of PRP due to lack of literature 
that systematically verified safety.
(4) Validity: On the validity assessment, the degree of healing or 
regenerating tissue and its term were analyzed as main medical 
results.
The systematic investigation of 2 literatures reported that the 
effect of using PRP to heal fracture, chronic skin ulcer, surgical 
wound, etc does not have clinical ground. The group using 
PRP showed lower effect in bone adhesion in the comparative 
study of re-combination human bone morphogenetic protein 
7 administered groups and there was a significant difference in 
healing ulcer on the chronic diabetes foot in the comparative 
study of cellulose/collagen operating group. Among 5 random 
clinic test studies that compared a group using PRP with another 
group without using PRP, 4 studies did not show significant 
differences in the degree of healing or regenerating tissue between 
the 2 studied groups. Although 1 literature showed results that 
PRP helped wound healing, 1) the study was a preliminary 
report, 2) the method of randomly allocating study targets was 
not specifically described, 3) due to the lack of comparison of 
equality between the test group and the contrast group at the 
commencement of study, it was difficult to generalize the results. 
Thus, the opinion of subcommittee was that it was difficult 
to verify the validity of PRP, because there was no significant 
difference in healing or regenerating tissue by using PRP in most 
studies.
(5) Suggestion: The nHTA commented that it was difficult to 
make a positive conclusion on the safety of “PRP” as per Article 
3, Section 6 of new health technology assessment and the safety 
and validity of the technology was not supported yet, because 
the effect on healing or regenerating tissue was not verified. The 
result of deliberation by the nHTA and the result of check-up by 
the subcommittee were reported to the Minister of Health and 
Welfare on May 10, 2010.
2. Position of HIRAS
Based on the above assessment by the nHTA, the HIRAS 
stated that using PRP for a purpose other than study was illegal, 
because the safety and validity of treatments using PRP were 
not verified, adding that medical charges claimed to patients 
beyond the coverage of insurance may be reimbursed (currently 
examined by legal team of HIRAS). Asked whether Prolotherapy 
with PRP currently in use was possible as a kind of prolotherapy, 
the HIRAS also answered that it was illegal. However, the study 
on the PRP and similar operation is currently requested, it is 
still re-examined, leaving the possibility to recognize the validity 
of treatment in the other muscular and skeletal areas except for 
cartilage regeneration.
Conclusions
Scientific evidence has not been established to evaluate the 
efficacy of PRP treatment on knee joints, and the clinical use 
of PRP is not recommended worldwide. In Korea, PRP and 
Prolotherapy using PRP are defined as illegal medical technology 
whose safety and validity are not yet verified by the Ministry 
of Health and Welfare and HIRAS on the basis of the results 
of deliberation by the nHTA. Practicing physicians should 
remember that PRP injection to patients by imposing medical 
charge is still illegal as per the current medical law in Korea.
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